Skip to main content
Autobound logo
Incyte10-K: Product launch

Anticipates regulatory decision and potential commercial launch of JAKAFI XR in mid-2026

Read at SEC EDGAR

What happened

After addressing an FDA complete response letter, the company is preparing for a potential launch of a new once-daily formulation of its blockbuster drug, JAKAFI. This will require new marketing, sales enablement, and commercial support to manage the product line extension.

Source

SEC EDGARFeb 10, 2026

Annual report (Form 10-K)

Incyte 10-K for FY2025

Filing excerpt

A response to the CRL has been submitted and we anticipate a regulatory decision and potential commercial launch in mid-2026.

sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-K: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Period
FY2025
Fiscal year end
12/31
Filed
Feb 10, 2026

More from Incyte

Company page →

More 10-K signals at other companies

The full record

From the Signal API record

Details

CIK
879169
Accession number
0000879169-26-000010
Timeframe
Next year
Filing year
2026
Why it matters
Go-to-market support
Signal category
Strategic

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Feb 17, 2026
signal_type
sec-10k
signal_subtype
productLaunch

Use this data

Get every 10-K signal for Incyte and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/3e074422-e5f5-4747-87ba-53e1a5def043 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "3e074422-e5f5-4747-87ba-53e1a5def043",
  "signal_type": "sec-10k",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-02-17T06:34:03.067+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "detail": "After addressing an FDA complete response letter, the company is preparing for a potential launch of a new once-daily formulation of its blockbuster drug, JAKAFI. This will require new marketing, sales enablement, and commercial support to manage the product line extension.",
    "metrics": {
      "timeframe": "next_year"
    },
    "summary": "Anticipates regulatory decision and potential commercial launch of JAKAFI XR in mid-2026",
    "excerpts": "A response to the CRL has been submitted and we anticipate a regulatory decision and potential commercial launch in mid-2026.",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm",
    "filing_date": "2026-02-10",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.